Alzheimer’s disease affects over 55 million people worldwide and has long been linked to toxic protein buildup and chronic inflammation in the brain.

MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T ...

Cancer immunotherapy, which primes the body's immune system to fight off tumors, has historically focused on harnessing T cells' natural ability to recognize and attack cancer cells. While this ...

An international research team studying mice and human tissue samples has uncovered why older people are more likely to suffer severely from the flu and suggest that their findings could be used to ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical ...

Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD)Advancing clinical program in severe pulmonary inflammatory ...

This year, the GATE Life Sciences 2026 exam will be organised by IIT Guwahati. The official GATE Life Sciences syllabus PDF ...

The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity ... as well as ...

IMNN-001 continues to show a favorable safety profile.

LC3-associated phagocytosis (LAP) is a specialized process for degrading dead cells, microbes or other particles. It plays a ...